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Background: The effect of vascular disrupting agents in tumour therapy depends on both the immediate vascular
shutdown, and on the following re-vascularization of the tumour. The aim of this study was to use a tumour model
to investigate whether endothelial outgrowth cells (EOCs) influenced the short term treatment efficiency of
combretastatin A-4 disodium phosphate (CA4P) and 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by increasing
EOC tumour recruitment.
Methods: In order to visualize the recruitment of EOCs to the tumours, umbilical cord blood derived human EOCs
were labelled with 111Indium-tropolone in a dose of 0.37 MBq pr 3×106 cells and were injected intravenously into
mice carrying a C3H mammary carcinoma on their right rear foot. DMXAA and CA4P in different concentrations
and at different exposure times were used to create a hypoxic environment in the C3H mammary carcinoma in the
mice. Three different mice strains with various degrees of functional immune system were used to study the
homing capability of EOCs.
Results: Our data showed that approximately 4% of the total injected radioactive dose per gram of tissue was
found in the tumour after treatment with CA4P and DMXAA. Regardless of the concentration and the treatment
duration, CA4P did not increase EOC recruitment to the tumour in comparison to EOC recruitment in control
tumours in any of the 3 mice strains studied.
Conclusion: Our data showed that regardless of the grade of the immune system, ranging from a fully working to
a fully compromised immune system, treatment with CA4P did not increase recruitment of xenotransplanted EOCs
to tumour tissue.
Keywords: Endothelial outgrowth cells, Vascular disrupting agents, CA4P, TumourBackground
Endothelial Progenitor Cells (EPCs) are a source of cells
that can participate in vasculogenesis [1]. They are able to
circulate, proliferate, and participate in the development
of a vascular network [2,3] as well as augmenting angio-
genesis through the secretion of angiogenic growth factors
[4,5]. Endothelial progenitor cells are a heterogeneous* Correspondence: Lotte@mr.au.dk
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unless otherwise stated.population which can be divided into several subpopula-
tions, which may differ in origin and function [5,6].The
EPCs are mobilised in response to tissue ischemia [7] and
may be involved in re-vascularization of tumour tissue fol-
lowing incomplete tumour treatment [3,8,9]. The endo-
thelial outgrowth cells (EOC) are a subtype of EPCs that
have clonogenic and proliferative potential [10-12] and
has been shown to increase tumour growth rates [13].
For data on bio-distribution the radioactive agent 111In-
dium (111In) is frequently used and in vivo studies has
earlier been performed with indium labelled EPCs [14,15]al Ltd. This is an Open Access article distributed under the terms of the Creative
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distribution properties in organs.
Tumours are characterised by a vascular network that
consists of immature blood vessels with large fenestrations
in the endothelial cell layer and in the basal membrane
[16]. When tumours reach a size of approximately –
1 mm3 further expansion depends critically on the devel-
opment of new vessels to maintain oxygen and nutrient
delivery [17,18]. The demand of new vessel formation for
expansion of tumour tissue has made the vasculature an
obvious target for anti-tumour therapy both in the form of
anti-angiogenic pharmaceuticals and by vascular disrupt-
ing agents (VDA) [19]. These drugs inhibit formation of
new blood vessels and target the existing vasculature in tu-
mours, respectively [19,20]. VDAs are known primarily to
mediate their effects on tumour blood vessels resulting in
a transient effect of therapy with tumour hypoxia, ische-
mia, and cell death as a result [19-23]. In this study we use
the VDA compounds Combretastatin A-4 disodium phos-
phate (CA4P) and 5,6-dimethylxanthenone-4-acetic acid
(DMXAA) both of which selectively mediate vascular shut-
down of existing vasculature inside solid tumors [24,25].
However these drugs exert their anti-vascular action in dif-
ferent approaches. CA4P is a tubulin binding agent that in-
hibit microtubule assembly [26] and it has been shown to
induce a peak in peripheral blood Endothelial Progenitor
Cells (EPC) concentration within 4 hours after treatment
[8,9]. DMXAA belongs to the group of flavonoids which
induce secretion of cytokines [27] and recruitment of im-
mune cells [28].
The hypoxia occurring after VDA treatment may stimu-
late the release of EPCs from the bone marrow and
thereby the recruitment of EPCs to the tumour in order to
increase the blood supply to the necrotic areas [29-32].
However, it is not fully settled to which extent EPC re-
cruitment to the tumour occurs, therefore the aim of the
present study was to analyse the degree of homing of
xenotransplanted 111Indium (111In) labelled EOCs in
tumour bearing mice after treatment with the VDA com-
pounds CA4P and DMXAA.
Methods
Animal and tumour models
All animal procedures were approved and conducted in
accordance with the institutional guidelines for the care of
laboratory animals and with the Danish Animal Experi-
ments Inspectorate’s approval. This study was performed
on female CDF1, NMRI-nu/nu mice, and CIAE-NOG
mice obtained from Taconic Laboratories (Ry, Denmark).
Ten-fourteen week-old mice were implanted with a C3H
mammary carcinoma subcutaneously in the right rear
foot. The derivation and maintenance of this tumour have
been described in detail previously [33]. Experiments were
performed when tumours reached approximately 200 mm3in size, which typically occurred 3 weeks after inoculation.
All experiments were performed using non-anesthetized
animals.
Drugs
The pro-drug CA4P and the active drug combretastatin
A4 (CA4) were supplied by OXiGENE, Inc. (Waltham,
MA, USA). DMXAA was provided by Dr. William
Denny at the University of Auckland, New Zealand. The
drugs were prepared fresh before each experiment, by
dissolving in saline, and were kept cold and protected
from light until used. For in vivo experiments, CA4P
was injected intraperitoneally (i.p.) in one of the follow-
ing doses; 25 mg/kg or 250 mg/kg. For cell viability
studies, CA4P and CA4 were used in a concentration
range of 0.1 to 10 μM. DMXAA was injected i.p. at a
dose of 20 mg/kg.
EOC cultures
Mononuclear cells (MNCs) were isolated from human
umbilical cord blood and the umbilical cord blood sam-
ples were collected from fresh placentas. The collection
and experimental procedure was performed with written
consent from the mothers and with permission from the
local ethical committee (Videnskabsetisk komité Region
Midtjylland, 1988/1349). MNCs were isolated by density
gradient centrifugation using ficoll paque plus (400 × g
for 30 minutes (min)) after a 1:3 dilution with phosphate
buffered saline (PBS). After three washes in PBS, CD34
positive cells were purified using magnetic cell separ-
ation (MACS) with CD34+ microbeads and LS columns
(Miltenyi Biotec, Lund, Sweden). Cells were seeded at a
density of 1–1.8 × 106 cells/2 cm2 on gelatin (Sigma-
Aldrich, Brondby, Denmark) coated 12 well plates and
were maintained in endothelial basal medium-2 (EBM-2)
supplemented with EGM-2 mv Single-Quots (EGM-2
mv medium, Lonza, Walkersville, MD, USA) for four
days. After day 4, the medium was changed every day for
the following week. For the rest of the culture period the
medium was changed every second day. Colonies with
cobblestone-like morphology appeared after 2–3 weeks
in culture. These cells were cultured until they formed
larger colonies. These colonies were expanded over sev-
eral passages by use of standard cell culture procedures.
All cells were maintained under standard conditions
(5% CO2, 37°C).
Endothelial progenitor cells that had gone through 4–
6 passages were analysed for a specified panel of cell sur-
face markers using Flow Cytometry (FACS Calibur or
FACSCanto™II, BD Biosciences, Brondby, Denmark) and
Flow Jo (version 9.3.1, Tree Star Inc., Ashland, OR).
Cells with a cell surface antigen profile of CD34+,
CD45- and, CD133- were considered to be endothelial
outgrowth cells as shown in other studies [34].
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For determination of cell proliferation and cell viability
upon treatment with CA4 and CA4P, EOCs were grown at
3.4 × 104 cells/2 ml EGM-2mv medium. The cells were
treated with either medium (control) or 0.1, 0.3, 1, 3 or
10 μM of either CA4 or CA4P and were incubated at 5%
CO2, 37°C for two hours. After incubation the medium
was changed. Cells were supplemented with fresh medium
after 2 and 4 days and were harvested either 2, 4, or 6 days
after VDA treatment. The cell count and viability were de-
termined using the Trypan blue exclusion test.
Radioactive labelling
EOCs were detached from culture flasks using trypsin
and were centrifuged (480 × g, 5 min). The cell suspen-
sion was incubated with 111 In-tropolone for 15 min at
37°C at a labelling dose of 0.37 MBq/3 × 106 cells. After
the incubation period, the cells were washed twice in
PBS and centrifuged at 400 × g for 10 min, before ad-
ministration into the mice. The details of EOC labelling,
retention and incorporation into the vasculature have
been described before [35].
Cell transplantation
Before transplantation, the 111In labelled cells were sus-
pended in a concentration of 3 × 106 cells/200 μl PBS im-
mediately before injection into recipient tumour-bearing
mice. Immune-competent, CDF1 mice (n = 5 in each of 9
groups) and immune-deficient, NMRI-nu/nu mice (n = 5
in each of 4 groups) and CIAE-NOG mice (n = 5 in each
of 3 group) were placed in a jig and cells were injected into
the tail vein of the mouse. Each mouse received 200 μl cell
suspension by intravenous injection.
Radioactivity tracing in mice
Twenty-four hours after injection of the 111In-tropolone
labelled cells, a sample of 150 μl blood was taken into
dry EDTA tubes from the sub-orbital sinus of each
mouse. Immediately after blood samples were taken, the
mice were killed by cervical dislocation and samples of
the tumour, heart, lung, liver, kidney, spleen, muscle, bone,
brain, intestine, and bladder were excised and weighed be-
fore measuring the radioactivity using a gamma counter
(Packard, Canberra Company, GMI, Minnesota, USA).
The radioactivity of the carcass of the mice was measured
using a dosi-calibrator (Amersham, Capintec Inc., New
jersey, USA). The specific activity in the organs was calcu-
lated as percent of the injected radioactive dose per gram
of tissue (%ID/g) after correction for radioactive decay.
Statistics
Results are presented as mean ± 1 SE. A Student’s t-test or
Mann–Whitney Rank Sum Test were used for pair wise
comparison and a one way ANOVA was used for multiplecomparisons between groups (Sigma plot version 12).
P < 0.05 was considered to indicate a significant difference.
Results
In vitro toxicity assay
To investigate the effect of CA4P on EOCs, we treated
EOCs in culture with medium (control) or different
doses of either the active compound CA4 or the pro-
drug CA4P for 2 hours and followed the cell cultures for
up to 6 days after treatment with VDA. As shown in
Figure 1a and c, we observed a decrease in cell viability
over time in both control groups as well as in all the ex-
amined CA4 concentration. This decrease, as shown in
Figure 1b, corresponded well with a high increase in cell
number in the cell culture wells, resulting in limited cap-
acity for the cells to adhere. This confluence provided
suboptimal cell conditions and to some extent cell death.
Moreover CA4P concentrations higher than 1 μM re-
sulted in decreased cell viability over time as well as a
total inhibition in their proliferation potential over time
as shown in Figure 1 c and d.
Distribution of 111In labelled EOCs in different mice strains
To gain information about 111In labelled EOCs in a
tumour model and clearance of these xenotransplanted
cells by the immune system, we administered 111In la-
belled human EOCs into the tail vein of 3 different mouse
strains and investigated the tracer distribution 24 hours
after administration.
Comparing the different mice strains, with immune
systems ranging from fully working to a fully compro-
mised immune system, Figure 2 shows, that the distribu-
tion pattern of the 111In labelled cells is merely the same
for control mice in all three mice strains. Most of the
111In activity is located in the liver, spleen, and kidneys.
Though non-significant, there is a small difference in the
amount of radioactivity in the spleen and the kidney-
with the fully immune compromised mice (CIEA-NOG)
having more 111In accumulated in the spleen and less in
the kidneys compared to the two other mice strains.
Distribution of 111In labelled EOCs after treatment with
25 mg/kg CA4P
To determine the effect of CA4P treatment on the distri-
bution of 111In labelled EOCs in a tumour model, we ad-
ministered 111In labelled human EOCs into the tail vein of
3 different mouse strains and investigated the tracer distri-
bution 24 hours after 25 mg/kg CA4P and EOC adminis-
tration. Overall, a similar amount of radioactive EOCs was
found (Figure 2) in the tumour in the 3 different mouse
strains used in this experiment. In the control mice and
mice treated with CA4P and EOCs at the same time, the
amount of radioactivity in the tumours corresponded to



































































































Figure 1 In vitro effect of 2 hour incubation of EOCs in the presence of CA4 or CA4P. EOCs were incubated for 2 hours in the presence of
0, 0.1, 0.3, 1, 3, or 10 μM CA4 or CA4P. After two hours fresh medium was added and the cells were cultured for additional 2, 4 or 6 days. (a) and
(c) Viability as a function of time in days in EOC cell cultures initially treated with different concentrations of CA4 or CA4P. (b) and (d) Cell number as a
function of time in days in EOC cell cultures initially treated with different concentrations of CA4 and CA4P. The initial starting value was a total of
9000 cells. Data is presented as mean ± 1 SE (n = 2 in each group).
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we injected these cells at various time points after CA4P
treatment in all three mice strains. As seen in Figure 2a,
b, and c, in the mice receiving CA4P 1 and 4 hours be-
fore EOC administration, the amount of radioactivity in
the tumours changed slightly, however 111In accumula-
tion in tumours was only significantly different from
controls in CIEA-NOG mice receiving the CA4P 4 hours
before EOC administration.
Distribution of 111In labelled EOCs after treatment with
250 mg/kg CA4P and 20 mg/kg DMXAA
As listed in Table 1, the necrotic fraction in tumours
from mice treated with 25 mg/kg CA4P was higher than
the necrotic fraction in control mice, but yet small. Ahigher dose of CA4P (250 mg/kg) increased the necrotic
fraction as compared to treatment with both 25 mg/kg
CA4P, and to the control tumours. DMXAA (20 mg/kg)
mediated the highest amount of tumour necrosis. For
that reason, and in order to induce a higher EOC re-
cruitment to tumours, we treated the mice with either a
higher dose of CA4P, (250 mg/kg) 4 hours before EOC
administration (Figure 3a) or with DMXAA (20 mg/kg)
4 hours before cell administration (Figure 3b). As seen
from Figure 3a and b, the distribution of the 111In signal
from all the examined organs was in the same range as
observed in animals treated with the low dose of CA4P
(Figure 2a). Figure 3a and b illustrates that neither
CA4P, (250 mg/kg), nor DMXAA (20 mg/kg) treatment
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Figure 2 Distribution of 111In labelled EOCs after treated of
mice with 25 mg/kg CA4P. Tissue distribution of radioactivity after
i.v. injection of 111In labelled EOCs in (a) CDF1 mice, (b) NMRI-nu/nu
and (c) CIAE-NOG mice. The mice were treated with CA4P at different
time points before administration of 111In labelled EOCs and control
mice received only labelled EOCs. All mice were sacrificed 24 hours
after experimental start. Data is presented as mean ± 1 SE (n = 5 in
each group). A one way ANOVA were used for comparison between
the different mice strains and between the control group and different
CA4P treatment groups in each organ in each mouse strain.
Bertelsen et al. BMC Cancer 2014, 14:903 Page 5 of 9
http://www.biomedcentral.com/1471-2407/14/903to tumours in control mice. In contrast, treatment with
DMXAA resulted in a significant lower amount of 111In
in the tumours when compared to the control mice.
Additionally, we analysed whether an increased time-
span for the DMXAA to mediate its effect changed the
recruitment of the labelled EOCs to the tumour. As
shown in Figure 3b, mice receiving DMXAA 4 hours
and 24 hours before EOCs had the same recruitment of
EOCs to the tumour site and this was significantly lower
than the EOC tumour recruitment in the control mice.
Discussion
It has been believed for decades that EOCs have the po-
tential to home to sites of hypoxia in response to signals
given from that area [31,37,38]. CA4P induce hypoxia
[39] and therefore the recruitment of EOCs to the
tumour could be increased after CA4P treatment in
order for EOCs to help in the angiogenic progression
[8,9,25]. In the present study, we determined the effect
of CA4P treatment on EOC recruitment to the tumour
in 3 different mice strains. We confirm a previous study
showing the presence of EOCs in the tumour 24 hours
after administration of these human derived EOCs [35],
but, we did not observe an increased recruitment of
EOCs to the tumour after CA4P treatment.
It has previously been shown that CA4 and CA4P is
toxic towards proliferating cells [21]. We analysed the ef-
fect of CA4, as well as its pro-drug CA4P on viability and
proliferation of EOCs in vitro and our results supported
these previous findings. Using the active compound CA4,
we observed a decreased viability; however, this decrease
could be explained by confluency in the cell culture result-
ing in cell death for some of the cells. Using CA4P, in con-
centrations higher than 1 μM, decreased cell viability over
time and mediated a total arrest in their proliferation
potential.
Although the in vitro results indicate potential toxicity
of CA4P towards EOCs, this effect may not be observed
in vivo as this pro-drug is rapidly cleaved into CA4 byTable 1 Necrotic fraction in C3H tumours in control and
VDA treated mice
Treatment Necrotic fraction
Control 18.8 ± 1.4*
CA4P (25 mg/kg) 25.4 ± 2.6*
Control 9.3 ± 1.9#
CA4P (250 mg/kg) 37.0 ± 4.3#
Control 7.4 ± 3.4§
DMXAA (20 mg/kg) 77.3 ± 4.5§
CA4P: Combrestatin A-4 disodium phosphate; DMXAA: 5,6-dimethylxanthenone-
4-acetic acid; *Anja B. Bohn, Lotte B. Bertelsen and Thomas Wittenborn
unpublished data; #Murata et al. [22], Radiother. Oncol. 60: 155–161;
§Murata et al. [36], Int. J. Hyperthermial. 17: 508–519. Data is presented
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Figure 3 Distribution of 111In labelled EOCs after treatment of mice with 250 mg/kg CA4P or 20 mg/kg DMXAA. Tissue distribution of
111In radioactivity in different tissues after i.v. injection of 111In labelled EOCs in CDF1 mice. (a) Control mice receiving only labelled EOCs or mice
treated with 250 mg/kg CA4P 4 hours prior to EOC administration. (b) Control mice receiving only labelled EOCs or mice treated with 20 mg/kg
DMXAA 4 hours or 24 prior to EOC administration. Data is presented as mean ± 1 SE (n = 5 in each group).
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[40] and is therefore in its active form before convention
with the EOCs.
Mobilization and functional incorporation of EPCs
into the tumour vasculature is essential for the growth
of some tumours, however, some tumour types or differ-
ent tumour grade and stage may be more dependent on
EPCs for their growth than other [38]. Therefore, we ex-
amined if CA4P treatment induced recruitment ofxenotransplanted EOCs to the tumour tissue. The C3H
mammary carcinoma used in these studies has been
shown to be comparable to clinical studies when study-
ing the effect of CA4P [41]. Earlier studies have also
shown that VDA treatment causes a peak in circulating
EPCs 4 hours after administration [8] and furthermore a
peak of EPCs was found in the blood and the tumour of
CA4P treated mice [9]. Therefore, we expected the CA4P-
mediated vascular damage to result in an increased
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found no significant increase in EOC recruitment at any
of the VDA doses or treatment intervals used, when com-
pared to control mice. Contradictory when examining,
fully immune-competent mice (CDF1 mice), mice with an
absent thymus (NMRI-nu/nu mice) and super immune
deficient mice (CIEA-NOG mice), we found nearly the
same degree of EOC recruitment to the tumour in control
and VDA treated mice. However, in the tumours of CIEA-
NOG mice we observed a small decrease in EOC recruit-
ment in CA4 treated mice compared to control mice, and
when these mice were treated with CA4P 4 hours prior
to cell administration this decrease was significant. In
immune-competent mice, cells like monocytes/-macro-
phages and T lymphocytes, participate in the angiogenic
process by secreting pro- and anti-inflammatory cytokines,
that could control endothelial cell proliferation, their sur-
vival and apoptosis, as well as their migration and activa-
tion [42]. The decreased recruitment of EOCs in the
tumour of CIEA-NOG mice could be caused by the lack of
functional T, B and NK cells and deficiencies in signalling,
including impaired cytokine production in these mice. This
could result in impaired signalling to the murine endothe-
lial cells as well as the xenotransplanted EOCs and there-
fore decreased recruitment of these cells to the tumour.
As mentioned above, we tested the recruitment of hu-
man derived EOCs in 3 different mice strains with differ-
ent degrees of operational immune systems. During the
time span examined, we found nearly the same degree of
EOC recruitment to the tumour exposed to a 25 mg/kg
CA4P as to tumours in control mice independent of mice
strains. A higher dose of CA4P was therefore chosen in
the CDF1 mice. Increasing the CA4P dose to 250 mg/kg
did, however, did not change the EOC recruitment to tu-
mours. These data indicated that either the CA4P me-
diated vascular injury was not causing a compensating
angiogenesis post treatment or that EOCs are not able to
reach the vessels to mediate the development of new ves-
sels within the time span examined. Hence, in order to in-
duce more vascular damage, we used the VDA compound
DMXAA, which induces a higher fraction of necrosis in
the C3H tumour (Table 1), and thus, theoretically could
cause recruitment of a larger pool of EOCs to the tumour.
Despite the fact that EOCs are believed to home to nec-
rotic tumour areas [2,13,43], we did not observe an in-
creased recruitment of these cells to the tumour in
response to any of the VDA treatments used in this study.
On the contrary, we observed a decreased recruitment of
EOCs when the necrotic fraction in the tumours in-
creased. We cannot exclude the possibility that either the
EOCs are somehow being prevented from reaching the
tumour areas, or that the tumour vessels preferentially are
recruiting murine EPCs and that these host cells are suffi-
cient to fulfil the need of vessel formation.Taylor et al. showed an increased amount of murine
EPCs in a tumour model, different from ours, days after
CA4P treatment. However, as several studies has shown
variable extent of EPC participation in tumour vasculature
[38] the use of different tumour type, grade, and sizes
makes it difficult to compare EPC recruitment across
studies. In this and a previous study we have shown that
xenotransplanted EOCs can be found in the tumour
24 hours after injection. The cells were, however, not
found in the endothelial lining of small vessels in the
tumour, but were present in the tumour rim where they
might have a paracrine signalling function.
In this study, we also show that most of the 111In ac-
tivity was found in the liver, spleen, and kidneys in all 3
mice strains. The most immune-compromised animal
(CIEA-NOG), had accumulated indium activity in the
spleen and less in the liver compared to the fully im-
mune competent mice (CDF1 mice) and mice with an
absent thymus (NMRI-nu/nu mice). The CIEA-NOG
mice will, as they lack both NK-, T- and B-cells, have a
lower amount of antibodies that can react against the
transplanted cells, resulting in a slower capture of
the transplanted cells in the spleen. It is, however,
possible to use all 3 mouse strains in these homing
experiments since the time span examined are rela-
tively short as to avoid an immune response from
the immune competent mice towards the xenotrans-
planted EOCs.Conclusion
In the present study, the effect of VDA treatment on
EOC recruitment to the tumour in 3 different mice
strains was examined. The recruitment and presence of
EOCs at the tumour site of both untreated and VDA
treated animals in the 3 different mice strains were dem-
onstrated using 111In labelled EOCs. However the results
did not demonstrate an increased recruitment of the
xenotransplanted EOCs to tumour tissue 24 hours after
treatment with CA4P or DMXAA.
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